Handful Of House Health Panelists Support Strong ACA And Device Tax Repeal

On the roster of the House Energy and Commerce and Ways and Means Committees in 2019 are members working toward both support of the Affordable Care Act and repeal of the device tax that helps fund it. Some on the committees, including all of the Democrats, back efforts to strengthen ACA in 2019, while many Democrats declined to repeal the device tax in a key 2018 vote. But 19 members of the panels voted to accomplish both goals.

LISBON, PORTUGAL - February 24, 2015: Photo of united states house of representatives page on a monitor screen through a magnifying glass. - Image

Democrats sitting on the health subpanels of Congress’ Energy and Commerce and Ways and Means Committees already have pledged publicly in the current Congress to stabilize and enhance most provisions of the ACA, in part to offset what they say are attempts by Republicans to dismantle it. Energy and Commerce Committee Chair Frank Pallone Jr., D-N.J., is a prime example; he promised to “stop the Republican sabotage of the ACA,” in 2019, at a Feb. 27 public briefing in Washington, DC, on the topic of Congress and health-care actions in the coming year. (Also see "US House Preview: Health Panels To Push Device Tax Repeal, Shutdown Contingency Bills In 2019" - Medtech Insight, 5 March, 2019.)

Simultaneously, some Democrats (57 out of 193 Dems in the entire House) and almost every GOP House member wanted to make a slight fix tothe ACA in the last session...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legislation

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.